News & Media

Events
Interim Report January - September 2020

Read more
Events
Interim Report January - June 2020

Read more
Events
Redeye Growth Day

Read more
Press release
Medivir appoints Yilmaz Mahshid as new CEO

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new...

Read more
Press release
FDA grants MIV-818 Orphan Drug Designation for the treatment of hepatocellular carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan...

Read more
Press release
Resolutions at the Annual General Meeting in Medivir on 5 May 2020

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2020

January – March Significant events during the quarter Data from the phase Ia study with MIV-818 in liver cancer patients presented...

Read more
Press release
Medivir receives positive opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan...

Read more
Press release
Medivir announces departure of Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that Linda Basse, Chief Medical Officer at Medivir will leave the company...

Read more
Press release
Medivir 2019 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the...

Read more
Press release
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m....

Read more
Press release
Medivir and Tango Therapeutics sign license agreement for preclinical asset

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech...

Read more